Longeveron shares Phase 2a laromestrocel data at AAIC 2026
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/30/2026
- Crude Inventory Fell 7.2 Million Barrels Last Week - EIA
- SoFi Technologies (SOFI) Tops Q2 EPS by 1c ; Offers Guidance
- Wall Street closes down sharply after Fed holds rates unchanged
- Grant Thornton Advisors to buy CBIZ in $5 billion deal, expand US accounting reach
- How will the S&P 500 react to today’s FOMC? JPM lays out the playbook
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
- After-Hours Stock Movers: GOOGL, TSLA, NOW, IBM, TXN, MOH, URI
Longeveron Announces Presentation of Clinical Data at the 2026 Alzheimer’s Association International Conference (AAIC) that Indicate Its Cellular Therapy Laromestrocel Reduced Neuroinflammation in P
July 13, 2026 7:05 AM EDTPoster Presentation at the 2026 Alzheimers Association International Conference (AAIC) entitled Laromestrocel Stabilizes Brain Inflammation In Key Alzheimers Disease Gray And White Matter Regions As Assessed Using Free Water MRI presented at July 13th In Person Poster Presentation SessionResults support a clinically relevant and long-lasting anti-inflammatory mechanism of action of laromestrocel in gray and white matter of the brain, indicate potential blood biomarker correlates with clinical outcomes, and support continued clinical development of laromestrocel for Alzheimers diseaseLongeveron has... More
